GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

XBIO · Jun 30, 2026

Xenetic Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001683168-26-006061General Corporate
Operating cash generation65thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-132.53% · OPTIONAL · VALID

Revenue growth28thOwn-history percentile · N=18
Evidence method

Yoy · gp.fundamentals.revenue

11.99% · CORE · VALID

Operating margin75thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-147.09% · CORE · VALID

R&D intensity15thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

83.56% · OPTIONAL · VALID

SBC intensity40thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

7.87% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Dec 31, 20210/5 normalizedLevel 3Mar 31, 20220/5 normalizedLevel 3Jun 30, 20220/5 normalizedLevel 3Sep 30, 20220/5 normalizedLevel 3Dec 31, 20224/5 normalizedLevel 3Mar 31, 20234/5 normalizedLevel 3Jun 30, 20234/5 normalizedLevel 3Sep 30, 20234/5 normalizedLevel 3Dec 31, 20235/5 normalizedLevel 3Mar 31, 20245/5 normalizedLevel 3Jun 30, 20245/5 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20245/5 normalizedLevel 3Mar 31, 20255/5 normalizedLevel 3Jun 30, 20255/5 normalizedLevel 3Sep 30, 20255/5 normalizedLevel 3Dec 31, 20255/5 normalizedLevel 3Mar 31, 20265/5 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 4
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-66.47%
Current
-132.53%
Delta
-66.06%
Growth Decreased
Previous
36.01%
Current
11.99%
Delta
-24.03%
Profitability Decreased
Previous
-62.23%
Current
-147.09%
Delta
-84.87%
R And D Intensity Increased
Previous
81.97%
Current
83.56%
Delta
1.59%
Sbc Intensity Increased
Previous
1.40%
Current
7.87%
Delta
6.46%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Dec 31, 2024
Similarity
81%
Compared
5 dimensions
Coverage
100%
Growth 19.4 · Profitability 12.5 · Sbc Intensity 27.5 · Cash Generation 22.5 · R And D Intensity 10.0
Dec 31, 2025
Similarity
80%
Compared
5 dimensions
Coverage
100%
Growth 16.0 · Profitability 15.0 · Sbc Intensity 35.0 · Cash Generation 15.0 · R And D Intensity 5.0
Mar 31, 2024
Similarity
80%
Compared
5 dimensions
Coverage
100%
Growth 27.8 · Profitability 13.5 · Sbc Intensity 9.2 · Cash Generation 3.5 · R And D Intensity 31.2
Sep 30, 2023
Similarity
78%
Compared
4 dimensions
Coverage
80%
Profitability 6.8 · Sbc Intensity 21.8 · Cash Generation 35.0 · R And D Intensity 12.3
Mar 31, 2023
Similarity
73%
Compared
4 dimensions
Coverage
80%
Profitability 25.0 · Sbc Intensity 40.0 · Cash Generation 23.9 · R And D Intensity 3.9
Research Graph

Related governed research

Analogous To · XBIO state analogue 3 →Analogous To · XBIO state analogue 5 →Analogous To · XBIO state analogue 1 →Analogous To · XBIO state analogue 4 →Compared To · Pharmaceutical Preparations peers →Analogous To · XBIO state analogue 2 →Has State · Xenetic Biosciences, Inc. →Transitioned To · XBIO Fundamental State →Transitioned To · XBIO CASH_GENERATION_DECREASED →Transitioned To · XBIO GROWTH_DECREASED →Transitioned To · XBIO PROFITABILITY_DECREASED →Transitioned To · XBIO R_AND_D_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.